Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
72
Recruiting, any sponsor type, condition "sickle cell"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed298
72 trials
Showing 1 to 25, recently updated first.
- The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06975865 · 192 participants (planned) · Start Aug 12, 2025 · Primary completion Jul 23, 2027
Drug: Rilzabrutinib; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Clovis, California · 64 sites in all
St. Jude Children's Research HospitalAcademic, hospital or other
NCT05583721 · 40 participants (planned) · Start Oct 10, 2023 · Primary completion Sep 2027
Drug: [13N]NH3; Lexiscan · For: Sickle Cell Disease
Sites: Memphis, Tennessee
Disc Medicine, IncIndustry
NCT07187973 · 24 participants (planned) · Start Jan 6, 2026 · Primary completion Jun 2027
Drug: DISC-3405 · For: Sickle Cell Disease
Sites: Birmingham, Alabama; San Francisco, California; Atlanta, Georgia · 11 sites in all
St. Jude Children's Research HospitalAcademic, hospital or other
NCT07616154 · 45 participants (planned) · Start Sep 10, 2026 · Primary completion Sep 2034
Drug: Cyclophosphamide 50mg; Abatacept and 6 more · For: Sickle Cell Disease
Sites: Memphis, Tennessee
- Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive CrisisPivotal-lookingRecruiting
Imam Abdulrahman Bin Faisal UniversityAcademic, hospital or other
NCT07188766 · 394 participants (planned) · Start Oct 5, 2025 · Primary completion Aug 2028
Drug: Sodium Chloride (NaCl) 0.9 %; Sodium Chloride (NaCl) 0.9 % · For: SCD; Vaso Occlussive Crisis
Sites: Dammam, Saudi Arabia; Dhahran, Saudi Arabia; Jubail, Saudi Arabia · 5 sites in all
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06439082 · 354 participants (planned) · Start Oct 24, 2024 · Primary completion Jul 2, 2029
Drug: Crizanlizumab; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Orange, California; Washington D.C., District of Columbia · 36 sites in all
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT05904093 · 35 participants (planned) · Start Dec 18, 2024 · Primary completion May 14, 2027
Drug: Fostamatinib · For: Sickle Cell Disorders; Sickle Cell Disease; Hemoglobin S and 2 more
Sites: Bethesda, Maryland
University of PennsylvaniaAcademic, hospital or other
NCT06665997 · 65 participants (planned) · Start Jun 26, 2025 · Primary completion Jul 31, 2028
Drug: Depot medroxyprogesterone acetate (DMPA) · For: Sickle Cell Disease (SCD); Vaso-Occlusive Pain Episode in Sickle Cell Disease
Sites: Atlanta, Georgia; Philadelphia, Pennsylvania
CSL BehringIndustry
NCT07224360 · 63 participants (planned) · Start Feb 2, 2026 · Primary completion Aug 15, 2028
Drug: Anumigilimab; Placebo · For: Sickle Cell Disease
Sites: Little Rock, Arkansas; Orange, California; Hollywood, Florida · 38 sites in all
- Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease EndotypeRecruiting
Biossil Inc.Industry
NCT07282210 · 65 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: Senicapoc; Placebo · For: Sickle Cell Disease; Sickle Cell Anaemia; Sickle Cell Anemia
Sites: Toronto, Canada; Montreal, Canada · 4 sites in all
- A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)Pivotal-lookingRecruiting
Agios Pharmaceuticals, Inc.Industry
NCT07656415 · 159 participants (planned) · Start Jul 21, 2026 · Primary completion Aug 2029
Drug: Mitapivat Matched Placebo; Mitapivat · For: Sickle Cell Disease
Sites: Indianapolis, Indiana; Grand Rapids, Michigan; Flowood, Mississippi · 5 sites in all
Ochuko OrherheAcademic, hospital or other
NCT07543289 · 100 participants (planned) · Start May 8, 2026 · Primary completion Apr 30, 2027
Drug: Hydroxyurea (HU) · For: Sickle Cell Disease
Sites: Ile-Ife, Nigeria
- A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06546670 · 161 participants (planned) · Start Aug 15, 2024 · Primary completion May 1, 2028
Drug: ITU512; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Miami, Florida; Boston, Massachusetts · 14 sites in all
Mitchell CairoAcademic, hospital or other
NCT04099966 · 20 participants (planned) · Start Apr 1, 2021 · Primary completion Dec 31, 2026
Drug: alpha beta depletion · For: Acute Leukemia; Severe Aplastic Anemia; Non-hodgkin Lymphoma and 6 more
Sites: Valhalla, New York
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07566494 · 25 participants (planned) · Start Jul 31, 2026 · Primary completion Apr 27, 2027
Drug: VAS-101 · For: Sickle Cell Disease, Hemolytic Anemia
Sites: Bethesda, Maryland
Daniel BauerAcademic, hospital or other
NCT07708350 · 5 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 2028
Drug: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein · For: Sickle Cell Disease; Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Sites: Boston, Massachusetts
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06147414 · 550 participants (planned) · Start Oct 23, 2024 · Primary completion May 2027
Drug: Blood sample · For: Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including; Sickle Cell Disease; Cystic Fibrosis and 12 more
Sites: Paris, France
Mark Walters, MDAcademic, hospital or other
NCT04774536 · 9 participants (planned) · Start Aug 22, 2025 · Primary completion Mar 1, 2030
Drug: CRISPR_SCD001 · For: Sickle Cell Disease
Sites: Davis, California; Los Angeles, California; Oakland, California
- Gene Editing For Sickle Cell DiseaseRecruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT06506461 · 25 participants (planned) · Start Mar 21, 2025 · Primary completion Dec 2029
Drug: Plerixafor; Busulfan and 2 more · For: Sickle Cell Disease
Sites: Memphis, Tennessee
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07599176 · 90 participants (planned) · Start Jul 8, 2026 · Primary completion Jun 30, 2032
Drug: Alemtuzumab; Abatacept · For: Sickle Cell Disease; Beta-thalassemia
Sites: Bethesda, Maryland
CSL BehringIndustry
NCT06699849 · 70 participants (planned) · Start Jul 10, 2025 · Primary completion Oct 22, 2027
Drug: CSL889; Placebo · For: Sickle Cell Disease Vaso-occlusive Crisis
Sites: Oakland, California; Orange, California; Washington D.C., District of Columbia · 30 sites in all
TheraviaIndustry
NCT06578507 · 50 participants (planned) · Start Jan 21, 2025 · Primary completion Feb 2028
Drug: Hydroxycarbamid · For: Sickle Cell Disease
Sites: Créteil, France; Jossigny, France; Le Kremlin-Bicêtre, France · 7 sites in all
EpiDestiny, Inc.Industry
NCT04055818 · 20 participants (planned) · Start Jan 24, 2020 · Primary completion Oct 30, 2028
Drug: Nicotinamide · For: Sickle Cell Disease
Sites: Chicago, Illinois
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT06313398 · 100 participants (planned) · Start May 17, 2024 · Primary completion May 1, 2029
Drug: Biotin-labeled red blood cells · For: Sickle Cell Disease; Thalassemia; Hemoglobinopathy
Sites: Bethesda, Maryland
Forma Therapeutics, Inc.Industry
NCT06198712 · 95 participants (planned) · Start Jan 12, 2023 · Primary completion Feb 23, 2028
Drug: Etavopivat · For: Sickle Cell Disease
Sites: Toronto, Canada; Lyon, France; Paris, France · 18 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.